BBOT Dips Close to Lows With One Cancer Drug Update Steering Trade
BridgeBio Oncology Therapeutics shares traded near $8.90 in early Nasdaq action Friday, down from Thursday’s close on light volume. No new company disclosures appeared, with the next major update—Phase 1 data for lead drug BBO-11818—expected in the second half of 2026. U.S. markets will close Monday for Memorial Day.